-
2025: Year in Review
Latest News
-
Break Up With Your CAGs: How Three Letters Could Change Huntington’s Disease
Scientists engineered stem cells with “interrupted” CAG repeats to break up the toxic stretch. This may stop expansion, and could improve problems in cells that model Huntington’s disease. This study suggests that DNA spelling can drive the disease.
-
Huntington's Disease Therapeutics Conference 2017 – Day 1
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 1
-
Enemy at the gates – huntingtin disrupts nuclear transport
Two recent studies show how a cellular border control system goes wrong in HD, opening new avenues for HD research.
-
FDA approves a new drug for symptoms of Huntington's disease
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease
-
Sheep leading the flock: metabolism and biomarkers in HD
Sheep can help us to identify HD biomarkers and recognize metabolic changes that occur before symptoms develop.
-
Weeding out the truth: can cannabis improve Huntington’s?
What can individual experiences with cannabis tell us about Huntington's disease?
-
Huntingtin grabs a hammer: DNA repair in HD
Huntingtin helps fix damaged DNA, a recent study suggests, under the direction of a gene repair protein called ATM.
-
The benefits of migration, highlighted in Huntington's disease
Is HD a developmental disease? HD stops neurons migrating in developing brain, but maybe we can get them going again
-
Treasure your exceptions – using outliers to understand Huntington's disease onset and progression
A new study provides the framework for finding factors that affect the onset and progression of HD
-
A powerful message: does a toxic RNA message molecule cause harm in Huntington's disease?
What if some problems in HD were due to something other than a harmful protein?
-
Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington's disease symptoms
Pfizer announces the 'Amaryllis' trial of a PDE-10 inhibitor drug failed to improve symptoms of HD
